Patrick Moriarty, MD
Clinical Pharmacology · Kansas City, KSNPI 1356443675
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Kaneka Medical America LLC accounts for 74.1% of it on its own, with 13 other manufacturers making up the rest.
Across 174 payments — averaging $2834.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kaneka Medical America LLC$365K
- Amgen$37K
- Amarin Pharma, Inc.$30K
- Sanofi-aventis U.S. LLC$18K
- Grifols, S.A.$14K
- Esperion Therapeutics, Inc.$14K
- plus $16K from 8 others
Across 348 payments — averaging $6071.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$991K
- Regeneron$375K
- Novartis$340K
- Ionis Pharmaceuticals, Inc.$129K
- Akcea Therapeutics, Inc.$109K
- Kowa Research Institute, Inc.$86K
- plus $84K from 6 others
What the payments were for
- Consulting fees$275,21756%
- Speaking & faculty fees$191,49839%
- Travel & lodging$22,0594%
- Food & beverage$4,3681%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kaneka Medical America LLC | 19 | $365,226 |
| Amgen | 48 | $36,977 |
| Amarin Pharma, Inc. | 39 | $29,618 |
| Sanofi-aventis U.S. LLC | 13 | $17,795 |
| Grifols, S.A. | 6 | $14,384 |
| Esperion Therapeutics, Inc. | 14 | $13,561 |
| Regeneron | 7 | $8,617 |
| Regeneron Healthcare Solutions, Inc. | 6 | $4,035 |
| Novartis | 17 | $2,182 |
| Eli Lilly | 1 | $600 |
| Daxor Corporation | 1 | $93 |
| Akcea Therapeutics, Inc. | 1 | $43 |
| AstraZeneca | 1 | $40 |
| Novo Nordisk | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Apheresis Machine$73,019
- Liposober$61,932
- LIPOSORBER$59,342
- Vascepa$28,982
- Repatha$28,741
- PRALUENT$16,708
- NEXLETOL$13,404
- NEXLIZET$13,265
- EVKEEZA$10,495
- DISEASE STATE$3,075
- PELACARSEN$1,908
How this compares
Too few clinical pharmacology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 1,134 | $835,177 |
| Praluent PenAlirocumab | 447 | $282,531 |
| VascepaIcosapent Ethyl | 272 | $206,142 |
| Icosapent Ethyl | 105 | $43,687 |
| MounjaroTirzepatide | 33 | $34,078 |
| NexletolBempedoic Acid | 48 | $32,340 |
| NexlizetBempedoic Acid/Ezetimibe | 30 | $31,542 |
| OzempicSemaglutide | 26 | $24,722 |
| LivaloPitavastatin Calcium | 19 | $11,802 |
| Ezetimibe | 490 | $11,428 |
| Rosuvastatin Calcium | 485 | $6,439 |
| Omega-3 Acid Ethyl Esters | 28 | $3,046 |
| Typhim ViTyphoid Vi Polysacch Vaccine | 12 | $1,813 |
| Fenofibrate | 43 | $1,160 |
| Metformin Hcl | 84 | $890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $13,561 | $63,88278 claims |
| Novo NordiskOzempic | $20 | $24,72226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical pharmacology providers in Kansason file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.